Acadia Pharmaceuticals | ACAD - Passivo Circulante





Passivo Circulante Alterar Data
Acadia Pharmaceuticals USD 361.44M 55.91M 2026-06
ALKERMES USD 662.09M 62.59M 2026-06
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
Biogen USD 3.92B 918.2M 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Cara Therapeutics USD 11.26M 216K 2026-03
Corcept Therapeutics USD 153.8M 4.62M 2026-06
Cytokinetics USD 181.43M 17.76M 2026-06
Eisai JPY 393.64B 53.39B 2026-06
Eli Lilly USD 47.74B 11.11B 2026-06
Incyte USD 1.31B 177.55M 2026-06
J&J USD 55.46B 562M 2026-09
Moderna USD 2.53B 139M 2026-06
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Prothena USD 11.66M 20.86M 2026-06
PTC Therapeutics USD 771.07M 152.54M 2026-06
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Vertex Pharmaceuticals USD 3.94B 57.3M 2026-06